Patients with high bleeding risk (HBR) criteria had a 2.99 times higher risk of major adverse cardiovascular events and a 2.28 times higher risk of major bleeding events compared to non-HBR patients.
The 2026 guideline introduces AHA/ACC Acute Pulmonary Embolism Clinical Categories to improve severity classification and evidence-based management of acute pulmonary embolism.
The Clinical Valve Coordinator is essential for improving access to care and patient outcomes in multidisciplinary teams managing valvular heart disease.
Luteolin improved left ventricular ejection fraction (LVEF) and reduced inflammatory factors in atherosclerotic mice, indicating potential as a cardiovascular protective agent.
Anxiety and depression significantly reduced treatment effectiveness and increased major cardiovascular adverse events in ACS patients after PCI, compared to those without these conditions.
DurAVR significantly reduced indexed flow displacement from 4.0%/cm² to 3.5%/cm² and indexed flow reversal ratio from 3.9%/cm² to 2.6%/cm², restoring flow to control values.
PCI before TAVR did not improve survival or reduce urgent revascularization but decreased nonurgent revascularization, with increased bleeding risk (OR 1.59).
Increased polygenic risk scores for coronary atherosclerosis were significantly associated with higher prevalence of obstructive CAD (OR 2.23, 95% CI 1.94–2.55).
High-risk TIA patients treated with DAPT had 2-day stroke risk of 0.8%, significantly lower than ABCD 2 predicted risk of 5.1%.
Atrial fibrillation-related coronary embolism was independently associated with worse in-hospital outcomes (OR 3.3) and long-term events (HR 2.5) compared to non-AF CE.